Q&A: Page 3

Exclusive interviews with industry leaders

  • Scientist pipetting sample into a multi well plate
    Image attribution tooltip
    iStock via Getty Images

    Why biomanufacturing is the next innovation frontier for genomic therapies

    While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

    Meagan Parrish • June 13, 2022
  • Editas Medicine CEO Gilmore O'Neill
    Image attribution tooltip
    Permission granted by Editas/Gilmore O'Neill

    First 90 Days: Editas Medicine's Gilmore O'Neill

    The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

    Michael Gibney • June 13, 2022
  • brain drug
    Image attribution tooltip
    Stock via Getty Images

    A combo of precision meds and diagnostics could disrupt mental healthcare

    HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

    Kelly Bilodeau • June 8, 2022
  • David Jimenez
    Image attribution tooltip

    Permission granted by David Jimenez.

    First 90 Days: Janssen Immunology's David Jimenez

    The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

    Taren Grom • June 6, 2022
  • Sosei Heptares CEO Chris Cargill
    Image attribution tooltip
    Permission granted by Sosei Heptares/Chris Cargill

    First 90 Days: Sosei Heptares' Chris Cargill

    The company’s new CEO is looking to drive growth through collaboration and transparency.

    Kim Ribbink • May 31, 2022
  • CEO of Syneos Health
    Image attribution tooltip

    Permission granted by Michelle Keefe. 

    First 90 Days: Syneos Health's Michelle Keefe

    The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

    Taren Grom • May 23, 2022
  • Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
    Image attribution tooltip
    Stock via Getty Images

    The UK-based company that's striving to overcome the limitations of T cell receptor innovation

    Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

    Kim Ribbink • May 23, 2022
  • Dozens of orange prescription bottles with white caps and labels layered in a jumple.
    Image attribution tooltip
    iStock via Getty Images

    Ironwood Pharmaceuticals is charting a course to become a giant in GI

    Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market. 

    Karissa Waddick • May 19, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    BriOri BioTech sets the stage for the comeback of Vioxx

    With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

    Kelly Bilodeau • May 17, 2022
  • Doctor examines DNA molecules on blurred background.
    Image attribution tooltip
    Natali_Mis via Getty Images

    Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

    Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

    Michael Gibney • May 17, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

    With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

    Taren Grom • May 9, 2022
  • Image attribution tooltip
    Stock via Getty Images

    One company's failed drug is this company's 'jewel'

    Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

    Meagan Parrish • May 2, 2022
  • Headshot of Alan Millar.
    Image attribution tooltip

    Permission granted by Alan Millar. 

    How an open platform can shake up the drug development process

    TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

    Kim Ribbink • April 28, 2022
  • Vital sign monitor in tablet PC.
    Image attribution tooltip
    iStock via Getty Images

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    Kelly Bilodeau • April 26, 2022
  • Scientists examines DNA models in modern Neurological Research Laboratory.
    Image attribution tooltip
    iStock via Getty Images

    How OliX Pharmaceuticals is riding the RNAi wave

    While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

    Karissa Waddick and Taren Grom • April 25, 2022
  • Image attribution tooltip
    Stock via Getty Images

    The cannabis vanguard: A rare disease company looks to pioneer in the space

    Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

    Jared Whitlock • April 21, 2022
  • Psychedelic drugs
    Image attribution tooltip
    iStock via Getty Images

    A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

    Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

    Alexandra Pecci • April 21, 2022
  • In this photo illustration, the Facebook and Instagram apps are seen on the screen of an iPhone on October 04, 2021 in San Anselmo, California.
    Image attribution tooltip
    Justin Sullivan / Staff via Getty Images

    How pharma can up its social media game

    Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities. 

    Karissa Waddick • April 18, 2022
  • Busy traffic in Downtown Los Angeles at dusk.
    Image attribution tooltip
    Yongyuan via Getty Images

    Biotech goes Hollywood

    A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

    Taren Grom • April 13, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Down but not out: How AVEO's CEO steered the company past an FDA rejection

    Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

    Kim Ribbink • April 5, 2022
  • Image attribution tooltip
    Real Chemistry/PharmaVoice

    Lessons from improv: Shankar Narayanan's 'yes, and' approach to healthcare leadership

    Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

    Taren Grom • April 4, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Time-saving tech lights Alcon's path into digital innovation

    Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

    Kim Ribbink • April 4, 2022
  • Image attribution tooltip

    Sangamo Therapeutics

    Sangamo has its finger on the next evolution of gene editing

    Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

    Taren Grom • March 31, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Rare Patient Voice's president is striving to create a five-star experience for patients

    Successful clinical trial recruitment depends on listening to and empowering patients.

    Kim Ribbink • March 23, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Why Astellas is adopting a 'focus area approach' to partnerships

    Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

    Kim Ribbink • March 22, 2022